United States
    Mara Aspinall

    Mara G. Aspinall

    Chair of the Board, OraSure Technologies, Inc.
    Partner, Illumina Ventures

    Mara G. Aspinall became a member of the Board in June 2017 and serves on the Audit Committee and the Compensation Committee. She is a Partner at Illumina Ventures, one of the pre-eminent genomics and precision health venture capital firms. Previously, Ms. Aspinall co-founded BlueStone Venture Partners. Prior to these positions, Ms. Aspinall served as President and CEO, Global Head of Roche Tissue Diagnostics/Ventana Medical Systems, a division of The Roche Group that provides tissue-based cancer diagnostic instruments, products, and services. Prior to that, she founded and served as CEO and Director of On-Q-ity, Inc., a diagnostic research company focused on improving cancer treatment through the capture of circulating tumor cells in a patient’s blood. Ms. Aspinall also spent 12 years with Genzyme Corporation, serving as President of the Genzyme Genetics division, a leading provider of esoteric and genetic tests for the reproductive, oncology, and personalized medicine markets, and as President of the Genzyme Pharmaceuticals division, a custom pharmaceutical intermediates provider. Ms. Aspinall began her career as a management consultant with Bain & Company. Ms. Aspinall holds an M.B.A from Harvard Business School and a B.A. in International Relations from Tufts University.

    Nancy J. Gagliano

    Nancy J. Gagliano, MD, MBA

    Managing Director, Granite Healthcare Advisors

    Nancy J. Gagliano, MD, MBA, became a Board member in November 2021 and serves as the Chairperson of both the Nominating and Corporate Governance Committee and the Compensation Committee. Dr. Gagliano has more than 35 years of experience as a senior healthcare physician executive and practicing physician in internal medicine. Dr. Gagliano most recently served as an executive leader of the National Institute of Health’s RADx Tech, Rapid Acceleration of Diagnostics program. In this position she has helped oversee over one billion dollars of sponsored programs to bring millions of new COVID-19 tests to market. Prior to her work for the National Institute of Health, Dr. Gagliano was the Chief Medical Officer of Culbert Healthcare Solutions, providing strategic guidance on healthcare consulting services. Before joining Culbert Healthcare, Dr. Gagliano spent six years with CVS Health holding senior leadership positions including as the Chief Medical Officer of Minute Clinic, and as a Senior Vice President overseeing key programs such as the enterprise smoking cessation program and the development of the company’s telemedicine program. Prior to her leadership roles at CVS Health, Dr. Gagliano was a practicing internal medicine physician and held numerous leadership positions at Massachusetts General Hospital and Massachusetts General Physicians Organization. Dr. Gagliano holds an M.D. from Harvard Medical School, an MBA from Northeastern University, and a Bachelor’s of Science Degree from Union College in Computer Science and Biology.

    Lelio Marmara

    Lelio Marmora

    Former Executive Director, Unitaid

    Lelio Marmora became a member of the board in June 2020 and serves on the Audit Committee and Nominating and Corporate Governance Committee. Mr. Marmora has held substantial roles managing global health and modernization of large-scale state investments in complex political environments. He has also played senior strategic, operational and resource mobilization roles at headquarters levels in a range of international agencies. He is the former Executive Director of Unitaid in Geneva, Switzerland, from 2014 to 2020, overseeing a portfolio of $1.5 billion in 100 countries. During his tenure, Unitaid tripled its portfolio, becoming one of the leading Global Health innovation initiatives. Prior to Unitaid, Mr. Marmora was Director for Africa and the Middle East at the Global Fund to Fight AIDS, TB and Malaria, overseeing a $4 billion portfolio. He also served as head of the Fund’s Latin America and the Caribbean Department. Earlier in his career, Mr. Marmora served in various capacities at a range of international organizations, including the World Bank, the Inter- American Development Bank and the United Nations Development Program, managing modernization of the State programs. Mr. Marmora graduated from the Université Panthéon-Assas (Paris II) with a Master’s degree in International Law and Administration of International Organizations.

    Carrie Eglinton Manner

    Carrie Eglinton Manner

    President and CEO, OraSure Technologies, Inc.

    Carrie Eglinton Manner was named President and Chief Executive Officer of OraSure Technologies in June 2022 and brings more than 25 years of healthcare leadership and transformation expertise to the Company. Prior to joining OraSure, Ms. Manner was Senior Vice President, Advanced & General Diagnostics Clinical Solutions, at Quest Diagnostics. In that role, she was responsible for bringing innovative diagnostic solutions to market in the areas of women’s health, neurology, oncology, cardiovascular, metabolic, endocrinology, infectious disease, and immunology testing services, as well as drug monitoring and toxicology. She also led Quest’s pharmaceutical services, AmeriPath/Dermpath, and international businesses, as well as their molecular genetics team in pioneering next-generation sequencing innovation. Prior to Quest Diagnostics, Ms. Eglinton Manner served for 20 years in a variety of leadership roles at GE Healthcare, a division of General Electric (GE). A champion for inclusion and diversity, Ms. Eglinton Manner was co-chair for Quest’s African American Employee Business Network and GE’s Women’s Network. Ms. Manner received a B.S. degree in mechanical engineering from University of Notre Dame.

    David Shulkin

    David Shulkin, M.D.

    President and Chief Executive Officer, Shulkin Solutions, Inc.

    David J. Shulkin, MD, joined the Board in 2020 and serves on both the Compensation Committee and the Nominating and Corporate Governance Committee. Since 2018, he has served as President and Chief Executive Officer of Shulkin Solutions, Inc., a company that promotes innovation in healthcare and advocates for veterans and underserved populations. From 2015 through 2018, Dr. Shulkin served in various capacities at the U.S. Department of Veterans Affairs (the "VA"), including as Secretary of the VA from 2017 to 2018 and as Under Secretary for Health from 2015 to 2017. Prior to his tenure at the VA, he served in executive leadership positions at Morristown Medical Center, Beth Israel Medical Center, Temple University Hospital, Drexel University School of Medicine, Doctor Quality, Inc. and the University of Pennsylvania Health System and Hospital of the University of Pennsylvania. Dr. Shulkin received a B.A. from Hampshire College and his M.D. from the Medical College of Pennsylvania. He also completed residencies in Internal Medicine at Yale University School of Medicine and University of Pittsburgh School of Medicine, was a Fellow in General Medicine at the University of Pittsburgh School of Medicine and was a Robert Wood Johnson Foundation Clinical Scholar at the University of Pennsylvania School of Medicine. He is certified by the American Board of Internal Medicine.

    Robert W. McMahon

    Robert W. McMahon

    Senior Vice President and Chief Financial Officer, Agilent Technologies

    Robert W. McMahon, CMA, MBA, joined the Board in July 2023 and is chair of the Audit Committee. He is currently Senior Vice President and Chief Financial Officer for Agilent Technologies where he is responsible for Finance, Audit, Treasury, Tax, and Investor Relations. He has extensive leadership experience in business growth, mergers and acquisitions, and consistently delivering results while increasing profitability and improving cash flow. In his role at Agilent, he managed the company’s financials through the COVID-19 pandemic, ensuring stability for their workforce while focusing on key investments, maintaining cash flow, and providing frequent and transparent communication to investors. He has also led new opportunities for business growth with strategies to increase deal profitability and implemented new digital business models. Prior to his work for Agilent, Mr. McMahon spent four years serving as Chief Financial Officer for Hologic, where he helped reshaped the product portfolio and significantly improved company performance and profitability. He also spent more than 20 years at Johnson & Johnson where he held numerous leadership positions and his key responsibilities spanned corporate finance, financial planning and analysis, financial roadmaps, portfolio optimization, enterprise valuation, divestiture management, and business leadership. Mr. McMahon holds an MBA in Finance from the University of Central Florida and a bachelor’s degree in Finance from the University of Florida.

    © OraSure Technologies Inc., 2024